Vericel Q3 revenue up 7% to $34.5M; guides FY2021 revenue $158-$161M

Vericel Corp

2021-Q3 EPS reported -$0.26 revenue$108,593,000

Q3 total net revenue $34.5M (+7% YoY); MACI $23.9M, Epicel $9.8M (+48% YoY).
Q3 net loss $4.9M ($0.11/sh) vs net income $3.6M in Q3 2020; non-GAAP adj. EBITDA $4.3M.
FY2021 guidance: revenue $158-$161M (27-30% YoY growth); gross margin ~70%; adj. EBITDA margin ~22%.
Cash and investments $119M, no debt; operating cash flow $3.6M in Q3.
NexoBrid BLA resubmission expected mid-2022; MACI biopsies growth >30% expected in 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.